[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100639164":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":10,"centralContacts":22,"locations":29,"responsibleParty":111,"collaborators":10,"id":113,"slug":114,"hasResults":115,"nctId":116,"briefTitle":117,"officialTitle":117,"acronym":10,"eligibilityCriteria":118,"healthyVolunteers":119,"sex":120,"minAge":121,"maxAge":122,"enrollmentInfo":123,"targetDuration":10,"studyType":126,"phases":10,"briefSummary":127,"conditions":128,"keywords":10,"overallStatus":32,"whyStopped":10,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":132,"startDateStruct":135,"completionDateStruct":137,"leadSponsor":139,"locationsCount":140},{"fullName":5,"class":6},"Sanofi","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Participants aged 6 weeks to 55 years old",null,"Participants vaccinated with MenQuadfi® for the first time as per ordinary healthcare setting at the day of inclusion",[13],"Biological: Meningococcal (Groups A, C, Y, W) Polysaccharide Tetanus Toxoid Conjugate Vaccine",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"BIOLOGICAL","Meningococcal (Groups A, C, Y, W) Polysaccharide Tetanus Toxoid Conjugate Vaccine","This study will not administer any treatment, only observe the treatment as prescribed in real-world clinical practice.",[9],[21],"MenQuadfi®",[23],{"name":24,"role":25,"phone":26,"phoneExt":27,"email":28},"Trial Transparency email recommended (Toll free for US & Canada)","CONTACT","800-633-1610","option 6","Contact-US@sanofi.com",[30,42,51,60,69,78,87,96,105],{"facility":31,"status":32,"city":33,"state":10,"zip":34,"country":35,"countryCode":10,"cosmosGeoPoint":36,"geoPoint":41,"contacts":10},"Investigational Site Number: 410009","RECRUITING","Busan","49408","South Korea",{"type":37,"coordinates":38},"Point",[39,40],129.03004,35.10168,{"lat":40,"lon":39},{"facility":43,"status":32,"city":44,"state":10,"zip":45,"country":35,"countryCode":10,"cosmosGeoPoint":46,"geoPoint":50,"contacts":10},"Investigational Site Number: 410011","Daegu","41794",{"type":37,"coordinates":47},[48,49],128.59111,35.87028,{"lat":49,"lon":48},{"facility":52,"status":32,"city":53,"state":10,"zip":54,"country":35,"countryCode":10,"cosmosGeoPoint":55,"geoPoint":59,"contacts":10},"Investigational Site Number: 410003","Goyang","10234",{"type":37,"coordinates":56},[57,58],127.19731,36.21689,{"lat":58,"lon":57},{"facility":61,"status":32,"city":62,"state":10,"zip":63,"country":35,"countryCode":10,"cosmosGeoPoint":64,"geoPoint":68,"contacts":10},"Investigational Site Number: 410008","Gwangju","61665",{"type":37,"coordinates":65},[66,67],126.91556,35.15472,{"lat":67,"lon":66},{"facility":70,"status":32,"city":71,"state":10,"zip":72,"country":35,"countryCode":10,"cosmosGeoPoint":73,"geoPoint":77,"contacts":10},"Investigational Site Number: 410010","Hanam","12919",{"type":37,"coordinates":74},[75,76],127.20556,37.54,{"lat":76,"lon":75},{"facility":79,"status":32,"city":80,"state":10,"zip":81,"country":35,"countryCode":10,"cosmosGeoPoint":82,"geoPoint":86,"contacts":10},"Investigational Site Number: 410006","Iksan","54639",{"type":37,"coordinates":83},[84,85],126.95444,35.94389,{"lat":85,"lon":84},{"facility":88,"status":32,"city":89,"state":10,"zip":90,"country":35,"countryCode":10,"cosmosGeoPoint":91,"geoPoint":95,"contacts":10},"Investigational Site Number: 410005","Seongnam","13558",{"type":37,"coordinates":92},[93,94],127.7548,36.4052,{"lat":94,"lon":93},{"facility":97,"status":32,"city":98,"state":10,"zip":99,"country":35,"countryCode":10,"cosmosGeoPoint":100,"geoPoint":104,"contacts":10},"Investigational Site Number: 410004","Seoul","06132",{"type":37,"coordinates":101},[102,103],126.9784,37.566,{"lat":103,"lon":102},{"facility":106,"status":32,"city":98,"state":10,"zip":107,"country":35,"countryCode":10,"cosmosGeoPoint":108,"geoPoint":110,"contacts":10},"Investigational Site Number: 410007","06614",{"type":37,"coordinates":109},[102,103],{"lat":103,"lon":102},{"type":112,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100639164","post-marketing-surveillance-study-for-menquadfi-meningococcal-groups-a-c-y-w-polysaccharide-tetanus-toxoid-conjugate-vaccine-administered-in-participants-aged-6-weeks-to-55-years-in-republic-of-korea-100639164",false,"NCT07621653","Post Marketing Surveillance Study for MenQuadfi® [Meningococcal (Groups A, C, Y, W) Polysaccharide Tetanus Toxoid Conjugate Vaccine] Administered in Participants Aged 6 Weeks to 55 Years in Republic of Korea","Inclusion Criteria:\n\n* Aged 6 weeks to 55 years on the day of MenQuadfi® vaccination\n* Evidence of a personally signed and dated informed consent document indicating that the participant or their parent(s)\u002Fother legally acceptable representative(s), if applicable, have been informed of all pertinent aspects of the study\n* Participants who have been vaccinated with MenQuadfi® for the first time as per ordinary healthcare setting at the day of inclusion in the study according to the approved local product label\n\nExclusion Criteria:\n\n* Participating or planning participation in any other clinical studies investigating a vaccine, drug, medical device, or medical procedure at the time of the study enrolment (or in 4 weeks preceding the enrolment)\n* Having a previous history of enrollment in this study (participants who have already been enrolled once in this study are not eligible for re-enrollment)\n* Being applicable to contraindications in the approved local product label of MenQuadfi®; anyone with a known systemic hypersensitivity reaction to any component of this vaccine or after previous administration of the vaccine or a vaccine containing the same components\n\nNote: The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial.",true,"ALL","6 Weeks","55 Years",{"count":124,"type":125},706,"ESTIMATED","OBSERVATIONAL","This surveillance is to investigate the safety profile of MenQuadfi®, when administered to participants aged 6 weeks to 55 years under the real-world clinical practice settings as per approved indications, including the Adverse Drug Reactions (ADRs)\\*.\n\n\\*It includes ADRs that were not fully recognized in clinical practice, or unexpected ADRs which refer to those not listed in the approved drug labeling.",[129,130],"Meningococcal Immunization","Healthy Volunteers","2026-07-28",{"date":133,"type":134},"2026-07-29","ACTUAL",{"date":136,"type":134},"2026-07-01",{"date":138,"type":125},"2027-11-23",{"name":5,"class":6},9]